Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas by Galleberg, R. B. et al.








EJSO 43 (2017) 1682e1689 www.ejso.comResults after surgical treatment of liver metastases in
patients with high-grade gastroenteropancreatic
neuroendocrine carcinomas
R.B. Galleberg a,*, U. Knigge b, E. Tiensuu Janson c,
L.W. Vestermark d, S.-P. Haugvik e, M. Ladekarl f, S.W. Langer g,
H. Grønbæk h, P. €Osterlund i, G.O. Hjortland j, J. Assmus k, L. Tang l,
A. Perren m, H. Sorbye a,n
aDepartment of Oncology, Haukeland University Hospital, Bergen, Norway
bDepartments of Surgery C and Endocrinology PE, Rigshospitalet, University of Copenhagen, Denmark
cDepartment of Medical Sciences, Uppsala University, Sweden
dDepartment of Oncology, Odense University Hospital, Denmark
eDepartment of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Norway
fDepartment of Oncology, Aarhus University Hospital, Denmark
gDepartment of Oncology, Rigshospitalet, University of Copenhagen, Denmark
hDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
iDepartment of Oncology, Helsinki University Central Hospital, Finland
jDepartment of Oncology, Oslo University Hospital, Norway
kCenter for Clinical Research, Haukeland University Hospital, Bergen, Norway
lDepartment of Pathology, MSKCC, New York, USA
mDepartment of Pathology, University of Bern, Switzerland
nDepartment of Clinical Science, University of Bergen, NorwayAccepted 21 April 2017
Available online 4 May 2017AbstractBackground: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high
aggressiveness and a dismal prognosis. Current international guidelines do not recommend surgical treatment of liver metastases, however
the existing data are scarce. The aim of this study was to evaluate the results of curatively intended resection/radiofrequency ablation (RFA)
of liver metastases in patients with metastatic GEP-NEC.
Methods: 32 patients with a diagnosis of high-grade gastroenteropancreatic neuroendocrine neoplasm (Ki-67 > 20%) and with intended
curative resection/RFA of liver metastases, were identified among 840 patients from two Nordic GEP-NEC registries. Tumor morphology
(well vs poor differentiation) was reassessed. Overall survival (OS) and progression-free survival (PFS) was assessed by KaplaneMeier
analyses for the entire cohort and for subgroups.
Results: Median OS after resection/RFA of liver metastases was 35.9 months (95%-CI: 20.6e51.3) with a five-year OS of 43%. The median
PFS was 8.4 months (95%-CI: 3.9e13). Four patients (13%) were disease-free after 5 years. Two patients had well-differentiated
morphology (NET G3) and 20 patients (63%) had Ki-67  55%. A Ki-67 < 55% and receiving adjuvant chemotherapy were statistically
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1683R.B. Galleberg et al. / EJSO 43 (2017) 1682e1689Conclusion: This study shows a long median and long term survival after liver surgery/RFA for these selected metastatic GEP-NEC pa-
tients, particularly for the group with a Ki-67 in the relatively lower G3 range. Our findings indicate a possible role for surgical treatment
of liver metastases in the management of this patient population.
 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Keywords: Neuroendocrine carcinoma; Metastases; Liver; Surgery; SurvivalIntroduction
Neuroendocrine carcinoma (NEC) is broadly defined as
a poorly differentiated neuroendocrine neoplasm (NEN)
with Ki-67 > 20% or mitotic rate>20/10 high-power
fields.1 In contrast to well differentiated NENs (WHO
G1eG2), NECs (WHO G3) are highly aggressive with a
propensity for early metastases and a dismal prognosis.2e6
At the time of diagnosis 57e88% of patients with gastroen-
teropancreatic NECs (GEP-NEC) have distant disease with
the liver as the main metastatic site.2,5e7 Patients with
localized GEP-NECs have a median survival of 16 months,
while for the group with metastases median survival is only
5 months.6 Current guidelines recommend platinum-based
chemotherapy as first-line treatment in the metastatic
setting.8e10 However, median survival is only 11e13
months and three-year survival 5e10% for these chemo-
therapy treated patients.5,7,11
Due to the highly aggressive behavior and high risk of
metastatic disease, the benefit of surgical treatment for
GEP-NEC patients has been questioned. International
guidelines currently recommend surgery for NENs G1/G2
with resectable liver metastases and in selected cases as de-
bulking surgery, while for GEP-NECs (WHO G3), surgery
in the metastatic setting is not recommended.12e14 Pub-
lished data to support these recommendations regarding
GEP-NECs are scarce. Two studies evaluating the role of
surgical resection of liver metastases in NEN patients,
found a median survival of 6e15 months for the minor
fraction of patients with poorly differentiated NENs.15,16
Two case reports describe long-term survival in GEP-
NEC patients after locoregional treatment of their liver
metastases.17,18
Thus the possible benefit of liver surgery in metastatic
GEP-NECs is unsettled. With our study we aim to further
evaluate the possible role of surgical treatment of liver me-
tastases in this patient population.Patients and methods
Patients with high-grade gastroenteropancreatic neuroen-
docrine neoplasm (WHO G3) with surgical treatment of
liver metastases were identified from two combined medi-
cal/surgical Nordic NEC registries. One registry is a retro-
spective GEP-NEC database consisting of 485 patients
diagnosed between 2000 and 2012. The second registry isa prospective GEP-NEC database of 355 patients, collected
from January 2013 to September 2015. Twelve Nordic ter-
tiary care institutions have submitted data. Informed consent
has been obtained from all patients, and the study has been
approved by the medical ethics committees of all partici-
pating countries. The inclusion criteria for the present study
were: Histopathological confirmed diagnosis of a high-grade
neuroendocrine neoplasm (NEN) with Ki-67 > 20%, a gas-
troenteropancreatic primary or an unknown primary with
predominantly abdominal tumor burden, either synchronous
or metachronous liver metastases, surgical resection and/or
RFA of metastatic disease in the liver with a curative intent.
RFAwas accepted as a treatment modality as published data
support a role for this approach when treating selected pa-
tients with limited size liver metastases from colorectal can-
cer with a curative intent.19 Tumor morphology was
classified as small-cell or non-small cell. A central review
to assess histological differentiation (well differentiated
morphology vs poorly differentiated morphology) was per-
formed by four experienced neuroendocrine pathologists
(LT, AP, JYS, BF). If the Ki-67 value was reported from
both the primary tumor and metastases, the higher value
was adopted. A cut-off value of 55% for Ki-67 was used
when performing statistical analyses.11 We chose to use
progression-free survival instead of disease-free survival as
some of our patients never became disease free. The patient
who died within 30 days of surgery was excluded from the
subgroup analysis comparing patients that did and did not
receive adjuvant chemotherapy. This was in order to avoid
potential bias as this patient died before chemotherapy could
be given. Previously described prognostic markers in GEP-
NEC patients were applied for subgroup analyses.11,15 Num-
ber of metastases is an important prognostic marker after he-
patic surgery for metastatic colorectal cancer, and was
therefore included in the analyses.20,21Statistical analyses
OS was defined as the time from surgical treatment of
liver metastases to last follow-up or death. PFS was defined
as the time from surgical treatment of liver metastases until
progression or recurrence of the disease. Descriptive
methods were used to characterize the patient population.
The survival was assessed by KaplaneMeier analyses for
the entire patient population and for subgroups (one criteria
at a time). We compared the subgroups by logrank and
Table 1







Sex: Male 32 19 (59.4%)
Median age (range) 32 55 (25e79)
Performance status (PS) 32
PS 0 27 (84.4%)
PS 1 4 (12.5%)
PS 2 1 (3.1%)






Other GI 2 (6.3%)




Distal pancreas resection 7 (50%)
Total pancreatectomy 2 (14.3%)





Small cell 7 (21.9%)
Non-small cell 25 (78.1%)
Differentiation 32
Poorly differentiated 24 (75.0%)
Well differentiated 2 (6.3%)
Inconclusive 1 (3.1%)













Left hepatectomi 3 (9.4%)
Right hepatectomi 6 (18.8%)
Atypical resection 5 (15.6%)
1 segment resected 8 (25.0%)
2 segments resected 7 (21.9%)
RFA combined with surgery 3 (9.4%)


























Other medical tumor treatment 5 (15.6%)
None 19 (59.4%)
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could not be approved we used the Breslow test as main cri-
terion and abstained from fitting a Cox model. The general
significance level was set to 0.05. All computation was
done using SPSS 22 (IBM Corp., Armonk, NY, 2013)
and the graphics were produced by Matlab 7.10 (The Math-
Works Inc., Natick, MA, 2010).
ResultsPatient characteristicsFrom the combined Nordic GEP-NEC registries of 840
patients, we identified 40 patients who had undergone surgi-
cal treatment of their liver metastases. Eight patients were
later excluded as they did not fulfill the inclusion criteria:
One patient was not operated on with a curative intent;
two patients underwent surgery several years before they
had a NEC diagnosis; one patient had a primary mixed ad-
enoneuroendocrine carcinoma (MANEC) and an adenocar-
cinoma removed from the liver; two patients had a Ki-
67  20% after pathological re-evaluation; one patient
had a large cell carcinoma with negative chromogranin A
and synaptophysin and, after pathological re-evaluation,
did not qualify as NEN. Among the remaining 32 patients,
29 had a known primary site and 27 of these had the primary
tumor resected. One patient lacked information regarding
surgical status of the primary tumor and one patient had
the liver metastases resected before the primary pancreatic
tumor was found. This pancreatic tumor was not resected.
The patients with unknown primary tumors had the diag-
nosis made on histology from liver biopsies. One of these
three patients underwent a right-sided hemicolectomy due
to a highly differentiated adenocarcinoma 2 months after
liver surgery. Some of the cells in the resected colon stained
positive for CgA and synaptophysin, and NEC was found in
the local lymph nodes. In 21 (66%) of the patients a NEC
diagnosis was present before surgery. Distant lymph node
involvement was reported for three patients, and these
lymph nodes were removed simultaneously with the liver
surgery in two of the patients. For the last patient relevant
information is missing. Six patients were treated solely
1685R.B. Galleberg et al. / EJSO 43 (2017) 1682e1689with RFA. Four of these had liver metastases <40 mm, the
last two with metastasis of 40 mm and 50 mm. The median
interval from the primary NEC diagnosis to the diagnosis of
liver metastases was 0 months (range 0e27 months) as most
patients had synchronous disease. From the diagnosis of
liver metastases to liver surgery the median interval was
1.5 month (range 0e57 months). The median interval be-
tween primary tumor resection and liver metastases resec-
tion/RFA was 0 months (range 2 to 29).The patients
were followed up for a median of 38 months (range 1e50
months). For the 12 patients still alive at the time of the
analysis, median follow-up was 46 months (range 23e184
months). Table 1 describes the different procedures per-
formed on the liver. The median diameter of the largest liver
metastasis was 3.5 cm (range 1e25 cm). Median Ki-67 was
60% (range 25e100%) and 63% of the patients had Ki-
67  55%. Twenty three patients (70%) were amenable
for the central pathological review of the morphology. For
three of the remaining patients the slides were evaluated
by one of the study pathologists, these three had Ki-67
values >80% and were all deemed poorly differentiated.
In one patient, with a Ki-67 of 60%, the degree of differen-
tiation could not be determined as the specimen was subop-
timal. For the remaining five patients the histological slidesFigure 1. Overall survival after surgical treatment of liver metastases in patients w
KaplaneMeier and stratified by prognostic markers. Overall survival for the enti
<55% (B), stratified by pancreatic primary versus non-pancreatic primary (C), acould not be located. These had Ki-67 values of 30%, 37%,
45%, 70% and 95%. A complete list of patient characteris-
tics is presented in Table 1.Overall survivalNo patients were lost to follow-up. The median overall
survival after liver surgery/RFA was 35.9 months (95%
CI 20.6e51.3) (Fig. 1a). Three-year survival after sur-
gery/RFA was 47% and 5-year survival 43% (Table 2). Pa-
tients with a Ki-67 of 21e54% had significantly longer
survival than the group with a higher Ki-67 (61.6 vs.
21.2 months P ¼ 0.018) (Fig. 1b). There was a trend to-
wards longer survival for the group with a pancreatic pri-
mary, however these results did not reach statistical
significance (40.6 vs. 21.2 months P ¼ 0.146) (Fig. 1c).
There was a statistically significant longer survival for the
group receiving adjuvant chemotherapy (66.8 vs.
29.9 months P ¼ 0.028) (Fig. 1d). No significant difference
was found when comparing the groups that did and did not
receive neoadjuvant chemotherapy (>29.9 vs.
35.7 months P ¼ 0.142) (Table 2). Only two of the 26 pa-
tients with a known differentiation status had well differen-
tiated tumor morphology (NET G3), these two had an OSith gastroenteropancreatic neuroendocrine carcinoma. Survival assessed by
re group treated with curative intent (A), stratified by Ki-67  55% versus
nd stratified by received versus not received adjuvant chemotherapy (D).
Table 2
Survival for 32 patients with surgically treated metastatic gastroenteropancreatic neuroendocrine carcinoma.
No. Patients Overall survival (months) P-value Progression free survival
(months)
P-value
Median (CI) 3-year 5-year Logrank Breslow Median (CI) 3-year 5-year Logrank Breslow
All patients 32 35.9 (20.6e51.3) 47% 43% 8.4 (3.9e13) 16% 13%
Ki-67 0.066 0.018 0.162 0.074
55% 20 21.2 (16.3e26.0) 38% 31% 5.0 (0.2e7.6) 10% 10%
21e54% 12 61.6 (21.8e101.5) 63% 63% 11.3 (8.1e14.4) 25% 17%
Primary tumor location 0.319 0.146 0.382 0.122
Pancreatic primary tumor 14 40.6 (32.7e48.5) 53% 44% 10 (7.0e13.0) 14% 14%
Non-pancreatic primary tumor 18 21.2 (15.7e26.7) 44% 44% 3.8 (0e8.0) 17% 11%
Number of metastases 0.451 0.536 0.198 0.292
0e2 metastases 18 61.6 (11.1e112.2) 60% 52% 10 (6.3e13.6) 22% 17%
>2 metastases 12 23 (2.25e43.7) 30% 30% 6.3 (2.3e10.1) 8% 8%
Adjuvant chemotherapy 0.028 0.057 0.068 0.031
Yes 13 66.8a 69% 69% 11.5 (7.5e15.4) 23% 23%
No 18 29.9 (10e49,8) 31% 24% 5.0 (0e11,2) 11% 6%
Neoadjuvant chemotherapy 0.142 0.528 0.148 0.259
Yes 12 >29.9 57% 57% 6.6 (0e16.4) 25% 25%
No 20 35.7 (14.1e57.2) 41% 34% 8.4 (0.35e16.5) 10% 5%
Complete macroscopic
resection or ablation
0.299 0.363 0.556 0.914
Yes 28 35.7 (17.6e53.8) 43% 38% 8.4 (2.0e14.8) 18% 14%
No 4 >30.5b 75% 75% 6.6 (4.3e9.0) 0% 0%
Differentiation 0.9 0.542 0.594 0.926
Well differentiated 2 35.9c 6.0d
Poorly differentiated 24 35.7 (13.5e57.9) 48% 42% 8.4 (4.0e12.8) 17% 13%
Radiofrequency ablation (RFA)e 0.084 0.374 0.430 0.885
Yes 9 29.9 (20.1e39.7) 0% 0% 8.4 (1.3e15.5) 0% 0%
No 22 61.6 (27.7e95.6) 64% 58% 8.7 (4.5e12.9) 23% 18%
Numbers in bold reflect significant differences in outcomes.
a Not computable.
b One died after 15.2 months, three still alive followed for 31 months, 43 months and 49 months.
c One died after 35.9 months. One is still alive after 22.6 months.
d One had recurrence after 6 months, one after 11.3 months.
e Six patients with isolated RFA, three patients with combined resection/RFA.
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presents OS for the entire material and subgroups.Recurrence and progression free survivalOf the 32 patients, 28 had recurrence (five-year PFS:
13%) (Fig. 2a). Three had local recurrence, eighteen had
hepatic recurrence, eight had lymph node recurrence, three
had pulmonary recurrence, one had bone recurrence and
five had recurrence in other localizations (ovary, cutaneous,
peritoneum). Four of the patients had simultaneous recur-
rence in several locations. Twenty-three of the recurrences
were treated with chemotherapy, five with surgery, two with
best supportive care and five with other modalities (liver
embolization, everolimus, interferon, somatostatin analog).
The median progression-free survival after liver surgery
was 8.4 months (95% CI 3.9e13) (Fig. 2a). In the group
of patients with a Ki-67 of 21e54% there was a trend to-
wards longer PFS than in the group of patients with
Ki67  55% (11.3 vs. 5.0 months P ¼ 0.074) (Fig. 2b).
Having a pancreatic primary did not significantly affect
PFS (40.6 vs. 21.2 months P ¼ 0.146) (Fig. 2c). Receiving
adjuvant chemotherapy significantly improved PFS (11.5 vs5.0 months P ¼ 0.031) (Fig. 2d). Table 2 presents PFS for
the entire material and subgroups.Postoperative complications after liver surgeryThere were no fatalities due to surgery. However, eleven
patients had one or more postoperative complications:
wound infection, abscess in the cicatrice, pancreatitis,
pneumonia, pancreatic leakage, small bowel obstruction,
portal vein thrombosis, pleural effusion and need for paren-
teral nutrition. The most serious adverse event was a post-
operative liver failure occurring due to only 17% remaining
liver tissue after resection of a 22 cm large liver metastasis.
This patient received a liver transplant one week after liver
resection and lived for 5 years before he died of NEC. Table
3 classifies the postoperative complications according to the
Clavien-Dindo classification.Characteristics of long-term survivors without
recurrenceThe four patients who were free from disease at the time
of analysis had been followed for a median of 72.5 months
Figure 2. Progression free survival after surgical treatment of liver metastases in patients with gastroenteropancreatic neuroendocrine carcinoma. Survival
assessed by KaplaneMeier and stratified by prognostic markers. Progression free survival for the entire group treated with curative intent (A), stratified
by Ki-67  55% versus <55% (B), stratified by pancreatic primary versus non-pancreatic primary (C), and stratified by received versus not received adjuvant
chemotherapy (D).
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NEC, one had a colonic NEC and one had a rectal NEC.
All had non-small cell morphology, three were poorly
differentiated and one had an unknown tumorTable 3
Postoperative complications after liver surgery in 32 patients with metasta-
tic gastroenteropancreatic neuroendocrine carcinoma.
Postoperative complications
according to the Clavien-Dindo
Number of patients
Grade I




- Abscess in the cicatrice 1
- Total parenteral nutrition 1
- Portal vein thrombosis 1
Grade III
- Pancreatitis 1
- Pancreatic leakage 1
- Pleural effusion 1
- Bowel obstruction 1
Grade IVa
- Liver failure 1differentiation. The Ki-67 was 30%, 70%, 90% and 90%.
The patients had few metastases (1e4) with a unilateral,
synchronous presentation. The median size of the largest
metastasis was 5.3 cm (range 3e20 cm). All resections
were R0. One patient received both neoadjuvant and adju-
vant cisplatin/etoposide, one patient did not receive any
chemotherapy and for the last two patients one received
neoadjuvant and one received adjuvant cisplatin/etoposide.
Discussion
As GEP-NEC is an aggressive disease with a median
survival of 11 months and 3-year survival of less than
10% after palliative chemotherapy, it is important to
explore alternative methods that could improve survival.11
The described 32 patients with liver surgery presented
with good performance status and most had liver surgery
close to the time of diagnosis, reflecting a low tumor
burden. The median OS of 35.9 months and 5-year survival
of 43% is surprisingly high and in contrast to results from
previous studies. Saxene and colleagues found a median OS
of 15 months for eleven patients with high grade NEC.16
However, their inclusion criteria and methods differ from
1688 R.B. Galleberg et al. / EJSO 43 (2017) 1682e1689ours in several aspects. The high grade NEC patients repre-
sented only a small fraction of their material (11/74) and
the surgery was not exclusively performed with a curative
intent, but in 35% also with a debulking purpose. Further-
more, patient characteristics regarding tumor load, tumor
grade (Ki-67-level), tumor differentiation and primary site
were not specified for the high-grade group. Cho and col-
leagues did a similar study on metastatic NEN patients
including seven high-grade cases.15 These patients survived
for a median of 6 months, but again relevant patient char-
acteristics are not described.
Recent studies have demonstrated a new subgroup of
neuroendocrine neoplasms with predominantly pancreatic
primaries and a high proliferation rate (Ki 67 > 20%),
which place them into the G3 category, but with histologi-
cally well-differentiated morphology, thus coined as NET
G3.22,23 However, the distinction between NET G3 and
NEC may be difficult to establish on routine pathologic
assessment.24,25 Survival for the NET-G3 subgroup appears
to be significantly longer than for patients with poorly
differentiated high-grade tumors.26 To ascertain that our ma-
terial did not exclusively consist of well-differentiated NET
G3 cases, four experienced neuroendocrine pathologists re-
examined available tumor slides. Only two of twenty-six pa-
tients had verified morphological well-differentiated tumors,
and this can therefore not explain the long survival in our
patients. In addition, given the higher incidence of NET
G3 in pancreatic primaries we compared pancreatic pri-
maries with the non-pancreatic primaries. This did not
reveal a significant difference in overall survival and
progression-free survival in this small sample size. Higher
proliferation rate in GEP-NEC is associated with signifi-
cantly worse OS.11,27,28 In the Nordic NEC study, median
OS was 14 months and 10 months for chemotherapy-
treated patients with Ki67: 21e55% and Ki67  55%
respectively.11 When we stratified our patients according
to Ki-67 level, the group with Ki-67: 21e54% had the
longest PFS and OS. However, also patients with a higher
Ki-67 seemed to benefit from surgical treatment of liver me-
tastases, with a median OS of 21.2 months and a 5-year sur-
vival of 31%. Our results seem to indicate a benefit from
receiving adjuvant chemotherapy, however, the patients
received a variety of regimens and specific recommenda-
tions are therefore hard to make. Of special interest are
the four patients without disease recurrence after a median
follow-up of 72 months. These patients seem to have been
cured of their disease. Unfortunately we could not identify
specific patient characteristics or treatment differences that
could explain the long term PFS for these four patients.
The possible benefit of surgical treatment must be weighed
against the risk of postoperative complications and of rapid
postoperative disease progression. In our cohort there were
no fatalities due to surgery, however the postoperative
complication rate was 22%.
Our study has some strengths and limitations. All pa-
tients are recruited from high-volume NEN centersreporting data to a central Nordic GEP-NEC database.
Therefore the patients are well characterized with clinical
and histopathological evaluation and with follow-up evalu-
ated by NEN experts. However, a limitation is the retro-
spective design with a risk of confounding factors. The
patients receiving surgical treatment of the liver metastases
are probably highly selected with good performance status,
low comorbidity, no progression during preoperative
chemotherapy and limited disease. Any comparison with
the surgically untreated liver-only metastatic patients is
therefore difficult. The criteria for liver surgery and neoad-
juvant/adjuvant chemotherapy depended on the local exper-
tise and were thus not consistent throughout this cohort. In
addition information regarding follow-up visits and imag-
ing performed is limited.
In conclusion, curatively intended surgical treatment of
liver metastases in selected GEP-NEC patients may be
considered as a part of the treatment plan, especially if
the Ki-67 is in the relatively lower G3 range. Further pro-
spective studies would be necessary to define clinical and
pathologic criteria for this treatment modality.
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